Studies on semaglutide have found that weight loss tends to increase as the dose increases, and a systematic review and meta-analysis confirmed a dose-response effect, meaning the benefits shift depending on how much you take
Schumer has been candid about her experience trying various weight-loss drugs, opening up in March about Mounjaro a GLP-1 drug similar to Ozempic
2 A 2025 meta-analysis of 50 randomised trials of GLP-1 receptor agonists found no increased overall cancer risk compared with placebo
The downsides of microdosing are its unknown effectiveness, sometimes increased risk of side effects because of non-monitoring, the potential for overdose due to overconsumption, and no guarantee of quality
But this is a different product targeting different endpoints
Stimulates Lipolysis Breaks down fats and lipids through hydrolyzation of triglycerides into glycerol and fatty acids